Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon s 2000 Revenues Triple While Losses Widen Sharply

NEW YORK, March 7 - Lexicon Genetics' year-end revenues increased 205 percent to $14.5 million from over $4.7 million in 1999, while increased expenses and stock compensation drove its losses up substantially for 2000, the company reported Wednesday.

The company attributed its revenue increase to a new alliance with Bristol-Myers Squibb in which Lexicon provides gene function information for drug targets in return for $15 to $25 million in access and delivery fees; as well as its other nine functional genomics collaborations with pharma and biotech; and license fees from its sub-licensees.

The jump in expenses, to $49.9 million in 2000 from $12.8 million in 1999, derives partially from a one-time stock-based compensation expense of $20.9 million. The company's sales, general, and administrative expenses also increased 168 percent to $8.3 million from $2.9 million in 1999, and its R&D expenses rose 42 percent to $20.8 million, from $14.6 million in 1999.

As part of its sales, general, and administrative expenses, Lexicon spent $800,000 pursuing patent infringement litigation against rival knockout mouse company Deltagen, a suit Lexicon initiated in late May.

The company posted net losses of $26.1 million or 63 cents per common share, compared to $13.0 million, or 53 cents per share for 1999.  These losses, which included the stock-based compensation, greatly exceeded Wall Street's expectation of 32 cents per share, based on a survey of two brokers conducted by FirstCall/Thomson Financial.

As of December 31, 2000, Lexicon had cash assets of $202 million in the bank. In April of 2000, the company filled its coffers with $220 million netted in an IPO.

"Lexicon performed exceptionally well in the year 2000 and met or exceeded all of our milestones," Arthur Sands, Lexicon CEO, said in a statement. "Our strong cash position and the power of our technology, combined with our highly experienced drug discovery team, places Lexicon on a trajectory to become a leading biopharmaceutical company of the post-genome era."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.